Adaptimmune Therapeutics Plc Financials

ADAP

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 39/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Adaptimmune Therapeutics Plc has an operating margin of -38.6%, meaning the company retains $-39 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -231.8% the prior year.

Growth

100

Adaptimmune Therapeutics Plc's revenue surged 195.3% year-over-year to $178.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Adaptimmune Therapeutics Plc has elevated debt relative to equity (D/E of 4.24), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.92, Adaptimmune Therapeutics Plc holds $2.92 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.

Cash Flow

While Adaptimmune Therapeutics Plc generated -$73.2M in operating cash flow, capex of $886K consumed most of it, leaving -$74.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Adaptimmune Therapeutics Plc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

1.03x

For every $1 of reported earnings, Adaptimmune Therapeutics Plc generates $1.03 in operating cash flow (-$73.2M OCF vs -$70.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-20.5x

Adaptimmune Therapeutics Plc earns $-20.5 in operating income for every $1 of interest expense (-$68.8M vs $3.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Adaptimmune Therapeutics Plc (ADAP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$178.0M

YoY+195.3%

5Y CAGR+175.5%

10Y CAGR+71.2%

Adaptimmune Therapeutics Plc generated $178.0M in revenue in fiscal year 2024. This represents an increase of 195.3% from the prior year.

EBITDA

-$57.5M

YoY+55.7%

Adaptimmune Therapeutics Plc's EBITDA was -$57.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.7% from the prior year.

Free Cash Flow

-$74.1M

YoY+49.1%

Adaptimmune Therapeutics Plc generated -$74.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 49.1% from the prior year.

Net Income

-$70.8M

YoY+37.8%

Adaptimmune Therapeutics Plc reported -$70.8M in net income in fiscal year 2024. This represents an increase of 37.8% from the prior year.

EPS (Diluted)

$-0.05

YoY+44.4%

Adaptimmune Therapeutics Plc earned $-0.05 per diluted share (EPS) in fiscal year 2024. This represents an increase of 44.4% from the prior year.

Cash & Debt

$91.1M

YoY-36.7%

5Y CAGR+12.6%

10Y CAGR+5.9%

Adaptimmune Therapeutics Plc held $91.1M in cash against $50.2M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

1.54B

YoY+12.7%

5Y CAGR+19.5%

10Y CAGR+23.8%

Adaptimmune Therapeutics Plc had 1.54B shares outstanding in fiscal year 2024. This represents an increase of 12.7% from the prior year.

Gross Margin

100.0%

Adaptimmune Therapeutics Plc's gross margin was 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.

Operating Margin

-38.6%

YoY+193.2pp

5Y CAGR+12418.6pp

10Y CAGR+1357.9pp

Adaptimmune Therapeutics Plc's operating margin was -38.6% in fiscal year 2024, reflecting core business profitability. This is up 193.2 percentage points from the prior year.

Net Margin

-39.8%

YoY+149.1pp

5Y CAGR+12185.3pp

10Y CAGR+1366.4pp

Adaptimmune Therapeutics Plc's net profit margin was -39.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 149.1 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$149.1M

YoY+17.8%

5Y CAGR+8.9%

10Y CAGR+31.6%

Adaptimmune Therapeutics Plc invested $149.1M in research and development in fiscal year 2024. This represents an increase of 17.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$886K

YoY-81.1%

5Y CAGR-11.1%

10Y CAGR-4.2%

Adaptimmune Therapeutics Plc invested $886K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 81.1% from the prior year.

ADAP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$178.0M+195.3%	$60.3M+122.0%	$27.1M+341.5%	$6.1M+55.4%	$4.0M+252.8%	$1.1M
Cost of Revenue	$70K	N/A	N/A	N/A	N/A	N/A
Gross Profit	$178.0M	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$149.1M+17.8%	$126.5M-1.0%	$127.7M+15.0%	$111.1M+21.3%	$91.6M-6.1%	$97.5M
SG&A Expenses	$87.3M+18.7%	$73.5M+16.0%	$63.4M+10.6%	$57.3M+25.1%	$45.8M+5.5%	$43.4M
Operating Income	-$68.8M+50.8%	-$139.7M+14.8%	-$164.0M-1.1%	-$162.2M-21.6%	-$133.4M+4.6%	-$139.8M
Interest Expense	$3.3M	N/A	N/A	N/A	N/A	N/A
Income Tax	$3.6M+167.7%	$1.3M-46.5%	$2.5M+215.7%	$791K+388.3%	$162K-33.1%	$242K
Net Income	-$70.8M+37.8%	-$113.9M+31.2%	-$165.5M-4.7%	-$158.1M-21.5%	-$130.1M+5.2%	-$137.2M
EPS (Diluted)	$-0.05+44.4%	$-0.09+47.1%	$-0.170.0%	$-0.17-13.3%	$-0.15+31.8%	$-0.22

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	$13.7M+87.7%	$7.3M+126.1%	$3.2M-92.1%	$40.9M+620.3%	$5.7M+2358.0%	$231K-96.8%	$7.3M+42.7%	$5.1M
Cost of Revenue	$2.5M+184.5%	$879K	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$11.2M+74.5%	$6.4M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$23.0M-20.4%	$28.9M-26.2%	$39.1M+14.0%	$34.3M-2.6%	$35.2M+6.0%	$33.2M-12.1%	$37.8M+26.1%	$30.0M
SG&A Expenses	$18.5M-20.6%	$23.3M-14.3%	$27.2M+27.7%	$21.3M+7.8%	$19.7M+16.9%	$16.9M+4.4%	$16.2M-19.5%	$20.1M
Operating Income	-$30.3M+33.8%	-$45.7M+37.8%	-$73.5M-400.8%	-$14.7M+70.2%	-$49.3M+1.2%	-$49.9M-6.9%	-$46.6M-3.8%	-$44.9M
Interest Expense	$962K-48.9%	$1.9M+257.6%	$526K-52.6%	$1.1M	N/A	N/A	N/A	N/A
Income Tax	$612K+6.4%	$575K-66.0%	$1.7M+103.7%	$831K+58.0%	$526K+180.2%	-$656K-195.5%	$687K+1.0%	$680K
Net Income	-$30.3M+36.2%	-$47.6M+35.9%	-$74.2M-321.3%	-$17.6M+63.7%	-$48.5M-1.2%	-$47.9M-5.1%	-$45.6M-113.2%	-$21.4M
EPS (Diluted)	$-0.02+33.3%	$-0.03+40.0%	$-0.05-400.0%	$-0.01+66.7%	$-0.03+25.0%	$-0.04-33.3%	$-0.03-50.0%	$-0.02

ADAP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$246.0M-13.0%	$282.6M-14.1%	$328.9M-30.0%	$469.5M+4.1%	$451.1M+148.5%	$181.5M
Current Assets	$188.2M-9.3%	$207.6M-18.7%	$255.4M-38.5%	$415.5M+4.3%	$398.2M+230.4%	$120.5M
Cash & Equivalents	$91.1M-36.7%	$144.0M+33.3%	$108.0M-28.0%	$149.9M+163.6%	$56.9M+12.8%	$50.4M
Inventory	$7.3M	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.5M+77.1%	$821K-89.0%	$7.4M+888.7%	$752K+441.0%	$139K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$234.1M-3.7%	$243.1M-1.6%	$247.0M-6.3%	$263.6M+139.8%	$109.9M+89.8%	$57.9M
Current Liabilities	$64.5M-11.3%	$72.8M+12.8%	$64.5M+3.1%	$62.5M+60.1%	$39.1M+13.8%	$34.3M
Long-Term Debt	$50.2M	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.8M-70.0%	$39.5M-51.7%	$81.9M-60.2%	$206.0M-39.6%	$341.2M+176.0%	$123.6M
Retained Earnings	-$1.1B-6.9%	-$1.0B-12.5%	-$909.3M-22.2%	-$743.8M-27.0%	-$585.8M-28.5%	-$455.7M

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$130.6M-17.4%	$158.1M-35.7%	$246.0M-22.5%	$317.4M+23.0%	$258.0M-8.7%	$282.6M-4.7%	$296.6M-13.5%	$343.0M
Current Assets	$78.1M-24.2%	$103.0M-45.3%	$188.2M-22.9%	$244.2M+30.7%	$186.9M-9.9%	$207.6M-5.4%	$219.4M-16.2%	$261.8M
Cash & Equivalents	$26.1M-36.5%	$41.1M-55.0%	$91.1M-21.9%	$116.7M-17.0%	$140.7M-2.3%	$144.0M+59.9%	$90.1M+17.0%	$77.0M
Inventory	$11.4M-3.0%	$11.8M+60.6%	$7.3M+290.6%	$1.9M	N/A	N/A	N/A	N/A
Accounts Receivable	$9.3M+112.5%	$4.4M+201.4%	$1.5M-88.4%	$12.5M+48.7%	$8.4M+923.6%	$821K+4.1%	$789K-73.4%	$3.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$201.6M+3.1%	$195.5M-16.5%	$234.1M-1.4%	$237.4M+1.6%	$233.6M-3.9%	$243.1M+16.6%	$208.5M-3.6%	$216.3M
Current Liabilities	$51.5M+0.9%	$51.1M-20.9%	$64.5M+1.7%	$63.5M-4.4%	$66.4M-8.8%	$72.8M-3.1%	$75.1M-1.3%	$76.1M
Long-Term Debt	$25.7M+1.0%	$25.4M-49.4%	$50.2M+0.7%	$49.9M	N/A	N/A	N/A	N/A
Total Equity	-$71.0M-89.6%	-$37.4M-415.9%	$11.8M-85.2%	$80.0M+228.2%	$24.4M-38.3%	$39.5M-55.2%	$88.1M-30.4%	$126.7M
Retained Earnings	-$1.2B-2.7%	-$1.1B-4.3%	-$1.1B-7.3%	-$1.0B+4.8%	-$1.1B-4.7%	-$1.0B-4.9%	-$975.3M-4.9%	-$929.7M

ADAP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$73.2M+48.0%	-$140.9M+0.6%	-$141.8M-1421.4%	$10.7M+120.0%	-$53.6M+52.4%	-$112.5M
Capital Expenditures	$886K-81.1%	$4.7M-84.1%	$29.5M+244.0%	$8.6M+266.3%	$2.3M+47.0%	$1.6M
Free Cash Flow	-$74.1M+49.1%	-$145.6M+15.0%	-$171.3M-8047.3%	$2.2M+103.9%	-$55.9M+51.0%	-$114.1M
Investing Cash Flow	-$59.0M-133.4%	$176.5M+98.1%	$89.1M+17.6%	$75.8M+127.2%	-$278.9M-393.8%	$94.9M
Financing Cash Flow	$78.7M+8848.8%	$880K-93.2%	$12.9M+291.3%	$3.3M-99.0%	$340.1M+92810.1%	$366K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Operating Cash Flow	-$34.8M+47.8%	-$66.6M-94.7%	-$34.2M+37.2%	-$54.5M-70.4%	-$31.9M-117.7%	-$14.7M+67.5%	-$45.2M-3.2%	-$43.8M
Capital Expenditures	$75K-93.8%	$1.2M+449.3%	$219K+53.1%	$143K+40.2%	$102K-87.7%	$827K+186.2%	$289K-76.2%	$1.2M
Free Cash Flow	-$34.9M+48.6%	-$67.8M-96.9%	-$34.4M+36.9%	-$54.6M-70.3%	-$32.1M-106.7%	-$15.5M+65.9%	-$45.4M-1.0%	-$45.0M
Investing Cash Flow	$18.5M-55.1%	$41.2M+403.9%	$8.2M+112.4%	-$66.0M-18340.8%	-$358K-100.5%	$68.2M+19.0%	$57.3M+2027.2%	$2.7M
Financing Cash Flow	$1.7M+106.5%	-$25.3M-2532100.0%	$1K-100.0%	$25.0M-14.5%	$29.2M+39406.8%	$74K-87.6%	$596K+4157.1%	$14K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ADAP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	100.0%	N/A	N/A	N/A	N/A	N/A
Operating Margin	-38.6%+193.2pp	-231.8%+372.1pp	-604.0%+2034.6pp	-2638.6%+731.9pp	-3370.5%+9086.7pp	-12457.2%
Net Margin	-39.8%+149.1pp	-188.9%+420.6pp	-609.5%+1961.5pp	-2571.0%+715.8pp	-3286.8%+8938.2pp	-12225.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-28.8%+11.5pp	-40.3%+10.0pp	-50.3%-16.6pp	-33.7%-4.8pp	-28.8%+46.7pp	-75.6%
Current Ratio	2.92+0.1	2.85-1.1	3.96-2.7	6.64-3.5	10.19+6.7	3.51
Debt-to-Equity	4.24-1.9	6.15+3.1	3.02+1.7	1.28+1.0	0.32-0.1	0.47
FCF Margin	-41.6%+199.8pp	-241.5%+389.4pp	-630.9%-665.9pp	35.0%+1448.2pp	-1413.1%+8756.1pp	-10169.3%

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	81.7%-6.2pp	87.9%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-221.5%+406.3pp	-627.8%+1654.0pp	-2281.8%-2245.9pp	-35.9%+831.7pp	-867.6%+20715.1pp	-21582.7%-20945.5pp	-637.1%+238.2pp	-875.4%
Net Margin	-221.8%+431.3pp	-653.2%+1650.2pp	-2303.4%-2260.3pp	-43.1%+811.2pp	-854.2%+19889.1pp	-20743.3%-20120.2pp	-623.1%-206.1pp	-416.9%
Return on Equity	N/A	N/A	72.2%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-23.2%+6.9pp	-30.1%+0.1pp	-30.2%-24.6pp	-5.5%+13.3pp	-18.8%-1.8pp	-17.0%-1.6pp	-15.4%-9.1pp	-6.2%
Current Ratio	1.52-0.5	2.02-0.9	2.92-0.9	3.85+1.0	2.81-0.0	2.85-0.1	2.92-0.5	3.44
Debt-to-Equity	-0.36+0.3	-0.68-4.9	4.24+3.6	0.62-9.0	9.59+3.4	6.15+3.8	2.37+0.7	1.71
FCF Margin	-254.8%+675.8pp	-930.6%+137.8pp	-1068.4%-934.9pp	-133.5%+431.0pp	-564.5%+6146.8pp	-6711.3%-6090.3pp	-621.0%+255.8pp	-876.8%

Similar Companies

Briacell Therapeutics Corp BCTX

$25.3M

Marker Therapeut MRKR

$23.8M

Biomx Inc PHGE

$9.8M

APOLLOMICS INC APLM

$42.4M

Phio Pharmaceuticals Corp PHIO

$17.8M

Frequently Asked Questions

What is Adaptimmune Therapeutics Plc's annual revenue?

Adaptimmune Therapeutics Plc (ADAP) reported $178.0M in total revenue for fiscal year 2024. This represents a 195.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Adaptimmune Therapeutics Plc's revenue growing?

Adaptimmune Therapeutics Plc (ADAP) revenue grew by 195.3% year-over-year, from $60.3M to $178.0M in fiscal year 2024.

Is Adaptimmune Therapeutics Plc profitable?

No, Adaptimmune Therapeutics Plc (ADAP) reported a net income of -$70.8M in fiscal year 2024, with a net profit margin of -39.8%.

What is Adaptimmune Therapeutics Plc's earnings per share (EPS)?

Adaptimmune Therapeutics Plc (ADAP) reported diluted earnings per share of $-0.05 for fiscal year 2024. This represents a 44.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Adaptimmune Therapeutics Plc's EBITDA?

Adaptimmune Therapeutics Plc (ADAP) had EBITDA of -$57.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Adaptimmune Therapeutics Plc have?

As of fiscal year 2024, Adaptimmune Therapeutics Plc (ADAP) had $91.1M in cash and equivalents against $50.2M in long-term debt.

What is Adaptimmune Therapeutics Plc's gross margin?

Adaptimmune Therapeutics Plc (ADAP) had a gross margin of 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Adaptimmune Therapeutics Plc's operating margin?

Adaptimmune Therapeutics Plc (ADAP) had an operating margin of -38.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Adaptimmune Therapeutics Plc's net profit margin?

Adaptimmune Therapeutics Plc (ADAP) had a net profit margin of -39.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Adaptimmune Therapeutics Plc's free cash flow?

Adaptimmune Therapeutics Plc (ADAP) generated -$74.1M in free cash flow during fiscal year 2024. This represents a 49.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Adaptimmune Therapeutics Plc's operating cash flow?

Adaptimmune Therapeutics Plc (ADAP) generated -$73.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Adaptimmune Therapeutics Plc's total assets?

Adaptimmune Therapeutics Plc (ADAP) had $246.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Adaptimmune Therapeutics Plc's capital expenditures?

Adaptimmune Therapeutics Plc (ADAP) invested $886K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Adaptimmune Therapeutics Plc spend on research and development?

Adaptimmune Therapeutics Plc (ADAP) invested $149.1M in research and development during fiscal year 2024.

How many shares does Adaptimmune Therapeutics Plc have outstanding?

Adaptimmune Therapeutics Plc (ADAP) had 1.54B shares outstanding as of fiscal year 2024.

What is Adaptimmune Therapeutics Plc's current ratio?

Adaptimmune Therapeutics Plc (ADAP) had a current ratio of 2.92 as of fiscal year 2024, which is generally considered healthy.

What is Adaptimmune Therapeutics Plc's debt-to-equity ratio?

Adaptimmune Therapeutics Plc (ADAP) had a debt-to-equity ratio of 4.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Adaptimmune Therapeutics Plc's return on assets (ROA)?

Adaptimmune Therapeutics Plc (ADAP) had a return on assets of -28.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Adaptimmune Therapeutics Plc's cash runway?

Based on fiscal year 2024 data, Adaptimmune Therapeutics Plc (ADAP) had $91.1M in cash against an annual operating cash burn of $73.2M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Adaptimmune Therapeutics Plc's Piotroski F-Score?

Adaptimmune Therapeutics Plc (ADAP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Adaptimmune Therapeutics Plc's earnings high quality?

Adaptimmune Therapeutics Plc (ADAP) has an earnings quality ratio of 1.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Adaptimmune Therapeutics Plc cover its interest payments?

Adaptimmune Therapeutics Plc (ADAP) has an interest coverage ratio of -20.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Adaptimmune Therapeutics Plc?

Adaptimmune Therapeutics Plc (ADAP) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.